1. Insulin/GLP-1 Agonist Combinations

3. Program Overview

4. Pathophysiology of Hyperglycemia

5. Updated ADA/EASD Standard of Care, 2017

6. Delays in Intensification of Therapy

7. The Role of Basal Insulin and GLP-1 RA in Controlling Hyperglycemia

8. Intensifying Therapy With Basal Insulin and GLP-1 RA

9. DUAL V: Key Results

10. DUAL VII: Key Results

11. LixiLan-O Trial: Study Design

12. LixiLan-L Trial: Study Design

13. LixiLan-O: Patients Achieving Composite Endpoints

14. LixiLan-L Trial: Change in HbA1c and Composite Endpoints

15. Simultaneous or Sequential Combination: LixiLan-O and GetGoal DUO-1 Trials

16. Simultaneous or Sequential Combination: LixiLan-O and GetGoal DUO-1 Trials (cont)

17. Simultaneous or Sequential Combination: LixiLan-L and GetGoal Duo-2 Trials

18. Shorter Time to Glycemic Control With IGlarLixi vs Gla-100: HbA1c

19. Shorter Time to Glycemic Control With IGlarLixi vs Gla-100: FPG

20. Shorter Time to Glycemic Control With IDegLira vs IDeg or Liraglutide

21. Patients Who Can Benefit Most From FRCs

22. LixiLan-L Subgroup Analyses

23. FRC of Insulin GLP-1 RAs: Key Considerations

24. Summary

25. Insulin/GLP-1 Agonist Combinations in Primary Care

26. Treating T2DM in Primary Care

27. FRCs of Basal Insulin/GLP-1 RA: Recap

28. The Role of FRCs in Primary Care

29. Which Patients Would Benefit Most in Primary Care?

30. Outlook

31. Abbreviations

32. Abbreviations (cont)